EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

Jennifer A Woyach iD, Relja Popovic iD, Emily L Rossi, Sanjana Singh, Toshihiko Oki, Tanya S Rosenberg, Chen Qian, Michael Moran iD, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R Furman und 5 weitere

American Journal of Hematology · 2026-07 · 101 (7) · 1516-1521

DOI: 10.1002/ajh.70275 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 08.04.2026. Verfasst von Jennifer A Woyach und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, The Ohio State University, Ohio, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc., AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BCL‐2BTKCLLmolecular predictorsnovel drug resistanceprecision medicine

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, The Ohio State University, Ohio, USA.
  • AbbVie Inc., Chicago, Illinois, USA.
  • Genentech Inc., South San Francisco, California, USA.
  • Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.

ORCID-Profile: Jennifer A Woyach, Relja Popovic, Michael Moran, Brenda Chyla, Matthew S Davids

Förderung

  • AbbVie Inc.
  • AbbVie

Zitieren

APA

Woyach, J. A., Popovic, R., Rossi, E. L., Singh, S., Oki, T., Rosenberg, T. S., Qian, C., Moran, M., Liu, Z., Boyer, M., Jones, J., Furman, R. R., Wierda, W., Gotlib, J., Schuster, S. J., Chyla, B., & Davids, M. S. (2026). Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up. American Journal of Hematology, 101(7), 1516-1521. https://doi.org/10.1002/ajh.70275

Vancouver

Woyach JA, Popovic R, Rossi EL, Singh S, Oki T, Rosenberg TS, et al. Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up. American Journal of Hematology. 2026;101(7):1516-1521. doi:10.1002/ajh.70275

BibTeX
@article{Woyach2026,
  author = {Woyach, Jennifer A and Popovic, Relja and Rossi, Emily L and Singh, Sanjana and Oki, Toshihiko and Rosenberg, Tanya S and Qian, Chen and Moran, Michael and Liu, Zihuan and Boyer, Michelle and Jones, Jeffrey and Furman, Richard R and Wierda, William and Gotlib, Jason and Schuster, Stephen J and Chyla, Brenda and Davids, Matthew S},
  title = {Recurrent Genomic Alterations in BCRi ‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1516--1521},
  doi = {10.1002/ajh.70275}
}
Kostenlos starten →